Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back

Omega Fund Management sold 411,968 Alumis shares in Q1, an estimated $10.3 million transaction, leaving it with 241,255 shares worth $5.31 million at quarter-end. The trimmed position still represented 3.3% of Omega's 13F AUM, suggesting profit-taking after Alumis' 327% 1-year rally rather than a full exit. Alumis also reported encouraging late-stage psoriasis data and said FDA submission remains on track for Q4, but the stock remains dependent on clinical execution and future lupus data.

Analysis

Omega’s trim is more interesting as a signaling event than a fundamental one: after a vertical rerating, active biotech holders often de-risk first and let data readouts decide whether to re-accumulate. That matters because the stock’s move has already pulled forward a lot of expected clinical success, so incremental buyers now need not just good data, but data that is clearly superior to competing TYK2 programs on durability, safety, and differentiation.

The second-order effect is that the real competition is no longer versus the broad market; it is versus other autoimmune asset owners trying to prove a cleaner path to approval and commercial share. If Alumis’ psoriasis and lupus package stays strong, the cash runway into late 2027 gives management time to negotiate from strength, but it also means the market will increasingly focus on whether the label is broad enough to support a meaningful franchise rather than a one-asset rally.

Near term, the biggest risk is the classic post-data fade: if upcoming readouts are merely consistent rather than unequivocally best-in-class, the stock can compress quickly as biotech quant and momentum capital de-grosses. The counterpoint is that the current holder base may still be underweight relative to the clinical optionality, so any surprise on lupus or regulatory feedback could trigger another leg higher over the next 1-3 months.

The market may be underestimating how much execution risk remains even with ample cash. With elevated R&D burn and a crowded autoimmune landscape, the path from encouraging PASI metrics to durable commercial value likely depends on one or two more clean catalysts; without them, this becomes a sentiment-driven name that can round-trip fast once the event calendar clears.

Key Decisions for Investors

• Short-dated options: buy ALMS downside puts into the next catalyst window if implied vol is reasonable; the setup favors a fast mean-reversion if follow-through data is only average, with downside likely to accelerate over 2-6 weeks.
• Pair trade: long a higher-quality late-stage autoimmune asset / short ALMS into the next readout to isolate differentiation risk; this is attractive if the market continues paying up for any TYK2 exposure without rewarding best-in-class proof.
• If holding ALMS, take partial profits on strength and re-enter only on post-event pullback; the stock has already priced in a lot of optimism, so upside is asymmetric only on a clear clinical or regulatory surprise.
• Watch for a post-lupus-data breakout or fail: above that catalyst, consider momentum longs for 1-3 months; if the data are mixed, fade rallies and target a 15-25% retracement as biotech holders rotate out.
• Avoid chasing the move on the basis of cash runway alone; in this tape, liquidity is a buffer, not a catalyst, and the trade should be driven by relative efficacy/safety evidence rather than balance-sheet comfort.